These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21440506)

  • 21. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
    Francini G; Paolelli L; Francini E; Pascucci A; Manganelli A; Salvestrini F; Petrioli R
    Eur J Surg Oncol; 2008 Feb; 34(2):216-21. PubMed ID: 17502132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combined radiotherapy and hormone therapy in non metastatic adenocarcinoma of prostate].
    Mazeron JJ; Simon JM; Toubiana T; Lang P
    Bull Cancer; 2005 Dec; 92(12):1078-84. PubMed ID: 16396754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
    Matveev BP; Bukharkin BV
    Urologiia; 2003; (6):6-10. PubMed ID: 14708235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
    Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
    J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabazitaxel for castration-resistant prostate cancer.
    Froehner M; Wirth MP
    Lancet; 2011 Jan; 377(9760):121-2; author reply 122-3. PubMed ID: 21215875
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of prostate cancer with hormonal therapy in Europe.
    Miller K; Anderson J; Abrahamsson PA
    BJU Int; 2009 Mar; 103 Suppl 2():2-6. PubMed ID: 19228146
    [No Abstract]   [Full Text] [Related]  

  • 27. Androgen deprivation in prostate cancer--step by step.
    Albertsen P
    N Engl J Med; 2009 Jun; 360(24):2572-4. PubMed ID: 19516038
    [No Abstract]   [Full Text] [Related]  

  • 28. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
    Scalliet P
    Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
    [No Abstract]   [Full Text] [Related]  

  • 29. A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.
    Armstrong JG; Gillham CM; Dunne MT; Fitzpatrick DA; Finn MA; Cannon ME; Taylor JC; O'Shea CM; Buckney SJ; Thirion PG
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):35-45. PubMed ID: 20797824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of neoadjuvant androgen deprivation before radical prostate radiotherapy.
    Parker C
    Lancet Oncol; 2005 Nov; 6(11):819-21. PubMed ID: 16257785
    [No Abstract]   [Full Text] [Related]  

  • 32. New study results highlight role of radiation therapy in prostate cancer.
    Reynolds T
    J Natl Cancer Inst; 2000 Dec; 92(23):1874. PubMed ID: 11106675
    [No Abstract]   [Full Text] [Related]  

  • 33. [Intermittent androgen blockade in prostatic carcinoma].
    Vachalovský V; Dvorácek J
    Cas Lek Cesk; 2002 Oct; 141(21):669-72. PubMed ID: 12564373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 35. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RE: Three-dimensional conformal radiotherapy in the treatment of prostate cancer in Australia and New Zealand: report on a survey of radiotherapy centres by K-H Tai et al.
    Izard MA
    Australas Radiol; 2005 Jun; 49(3):256-7. PubMed ID: 15932473
    [No Abstract]   [Full Text] [Related]  

  • 37. Cabazitaxel for castration-resistant prostate cancer.
    Shigeta K; Miura Y; Naito Y; Takano T
    Lancet; 2011 Jan; 377(9760):121; author reply 122-3. PubMed ID: 21215876
    [No Abstract]   [Full Text] [Related]  

  • 38. Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413.
    Taussky D; Bae K; Bahary JP; Roach M; Lawton CA; Shipley WU; Sandler HM
    Urology; 2008 Nov; 72(5):1125-9. PubMed ID: 18314175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
    Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Step up therapy].
    Shiono A; Kurokawa K; Ito K; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():292-4. PubMed ID: 11022732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.